Literature DB >> 26773186

Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis.

Arzu Duran1, Senol Kobak, Nazime Sen, Seniha Aktakka, Tennur Atabay, Mehmet Orman.   

Abstract

Calprotectin is one of the major antimicrobial S100 leucocyte proteins. Serum calprotectin levels are associated with certain inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The aim of this study was to investigate serum and fecal calprotectin levels in patients with ankylosing spondylitis (AS) and show their potential relations to the clinical findings of the disease. Fifty-one patients fulfilling the New York criteria of AS and 43 healthy age- and gender-matched volunteers were included in the study. Physical and locomotor system examinations were performed and history data were obtained for all patients. Disease activity parameters were assessed together with anthropometric parameters. Routine laboratory examinations and genetic testing (HLA-B27) were performed. Serum calprotectin levels and fecal calprotectin levels were measured by an enzyme-linked immunosorbent assay. The mean age of the patients was 41.5 years, the mean duration of the disease was 8.6 years, and the delay in diagnosis was 4.2 years. Serum calprotectin levels were similar in both AS patients and in the control group (p=0.233). Serum calprotectin level was correlated with Bath AS disease activity index (BASDAI) and Bath AS functional index (BASFI) (p=0.001, p=0.002, respectively). A higher level of fecal calprotectin was detected in AS patients when compared with the control group. A statistically significant correlation between fecal calprotectin level and BASDAI, BASFI, C-reactive protein and Erythrocyte sedimentation rate were detected (p=0.002, p=0.005, p=0.001, p=0.002, respectively). The results indicated that fecal calprotectin levels were associated with AS disease findings and activity parameters. Calprotectin is a vital disease activity biomarker for AS and may have an important role in the pathogenesis of the disease. Multi-centered prospective studies are needed in order to provide further insight.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26773186      PMCID: PMC4765943          DOI: 10.17305/bjbms.2016.752

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  17 in total

1.  Evaluation of the Quantum Blue® rapid test for faecal calprotectin.

Authors:  Julie Wassell; Michael Wallage; Ella Brewer
Journal:  Ann Clin Biochem       Date:  2011-09-19       Impact factor: 2.057

Review 2.  Ankylosing spondylitis and bowel disease.

Authors:  Martin Rudwaleit; Dominique Baeten
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-06       Impact factor: 4.098

Review 3.  Role of fecal calprotectin in gastrointestinal disorders.

Authors:  M Montalto; A Gallo; L Santoro; F D'Onofrio; R Landolfi; A Gasbarrini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-06       Impact factor: 3.507

4.  [Fecal calprotectin concentration in the differential diagnosis of bowel diseases].

Authors:  M F Osipenko; M A Livzan; M I Skalinskaya; E A Lyalyukova
Journal:  Ter Arkh       Date:  2015       Impact factor: 0.467

5.  Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum.

Authors:  Eva Klingberg; Hans Carlsten; Elisabet Hilme; Martin Hedberg; Helena Forsblad-d'Elia
Journal:  Scand J Gastroenterol       Date:  2012-01-10       Impact factor: 2.423

6.  Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study.

Authors:  H Mielants; E M Veys; S Goemaere; K Goethals; C Cuvelier; M De Vos
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

Review 7.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

8.  Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.

Authors:  Michael Manz; Emanuel Burri; Claude Rothen; Nuschin Tchanguizi; Christian Niederberger; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067

Review 9.  The link between ankylosing spondylitis, Crohn's disease, Klebsiella, and starch consumption.

Authors:  Taha Rashid; Clyde Wilson; Alan Ebringer
Journal:  Clin Dev Immunol       Date:  2013-05-27

Review 10.  Microbes, the gut and ankylosing spondylitis.

Authors:  Mary-Ellen Costello; Dirk Elewaut; Tony J Kenna; Matthew A Brown
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  11 in total

Review 1.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

2.  Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease.

Authors:  Latika Gupta; Shruti Bhattacharya; Vikas Agarwal; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2016-10-13       Impact factor: 2.980

Review 3.  Calprotectin in rheumatic diseases.

Authors:  Francesca Ometto; Lara Friso; Davide Astorri; Costantino Botsios; Bernd Raffeiner; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-01

4.  Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis.

Authors:  Fangze Zhang; Cuili Ma; Bin Zhang; Liqi Bi
Journal:  Clin Rheumatol       Date:  2020-03-26       Impact factor: 2.980

5.  The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behçet's Disease.

Authors:  Burak Özşeker; Cem Şahin; Havva Solak Özşeker; S Cumali Efe; Taylan Kav; Yusuf Bayraktar
Journal:  Dis Markers       Date:  2016-08-24       Impact factor: 3.434

6.  A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.

Authors:  Eva Klingberg; Hans Strid; Arne Ståhl; Anna Deminger; Hans Carlsten; Lena Öhman; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2017-02-02       Impact factor: 5.156

7.  Dissecting the Underlying Pharmaceutical Mechanism of Chinese Traditional Medicine Yun-Pi-Yi-Shen-Tong-Du-Tang Acting on Ankylosing Spondylitis through Systems Biology Approaches.

Authors:  Duoli Xie; Lin Huang; Guanghui Zhao; Yiran Yu; Jiawei Gao; Haichang Li; Chengping Wen
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

8.  Association of circulating calprotectin with lipid profile in axial spondyloarthritis.

Authors:  Fernanda Genre; Javier Rueda-Gotor; Sara Remuzgo-Martínez; Alfonso Corrales; Verónica Mijares; Rosa Expósito; Cristina Mata; Virginia Portilla; Ricardo Blanco; José Luis Hernández; Javier Llorca; Oreste Gualillo; Raquel López-Mejías; Miguel A González-Gay
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

Review 9.  Recent advances in ankylosing spondylitis: understanding the disease and management.

Authors:  Leticia Garcia-Montoya; Hanna Gul; Paul Emery
Journal:  F1000Res       Date:  2018-09-21

10.  Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice.

Authors:  Hyemin Jeong; In Young Kim; Eun-Kyung Bae; Chan Hong Jeon; Kwang-Sung Ahn; Hoon-Suk Cha
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.